ChemMedChem

Cover image for Vol. 12 Issue 10

Editorial Board Chairs: Antonello Mai, Rainer Metternich. Assoc. Editors: David Peralta, Scott Williams (Sr)

Impact Factor: 2.98

ISI Journal Citation Reports © Ranking: 2015: 18/59 (Chemistry Medicinal); 77/255 (Pharmacology & Pharmacy)

Online ISSN: 1860-7187

Associated Title(s): Angewandte Chemie International Edition, Chemistry - A European Journal, Chemistry – An Asian Journal, ChemBioChem, Medicinal Research Reviews, Molecular Informatics

Recently Published Issues

See all

Latest News

Browse more news

May 23, 2017

VIP: Neladenoson Bialanate Hydrochloride: A Prodrug of a Partial Adenosine A1 Receptor Agonist

VIP: Neladenoson Bialanate Hydrochloride: A Prodrug of a Partial Adenosine A1 Receptor AgonistDr. Daniel Meibom,* Dr. Barbara Albrecht-Küpper,* et al.

Adenosine is the emergency molecule that protects the body from tissue injury during ischemic events. It acts on four different receptors. Activation of adenosine A1 receptors has been shown to be responsible for protective processes in the heart during ischemia, suggesting new options for cardiovascular therapies. However, undesired physiological effects in the heart such as bradycardia and widespread tissue distribution of the A1 receptor makes use of the pharmacological pathways challenging. Read more...

Your Comment...

[Browse more news]

Recently Published Articles

  1. Targeting DNA-Dependent Protein Kinase for Cancer Therapy

    Dr. Suzannah J. Harnor, Alfie Brennan and Dr. Céline Cano

    Version of Record online: 29 MAY 2017 | DOI: 10.1002/cmdc.201700143

    Thumbnail image of graphical abstract

    Stopping the fixer: The catalytic activity of DNA-dependent protein kinase (DNA-PK) is critical to its ability to repair lethal DNA double-strand breaks, and many attempts have been made to identify small-molecule inhibitors of DNA-PK activity as an approach to induce tumour chemo- and radiosensitisation. DNA-PK catalytic inhibitors have now progressed into clinical development, which should help to further advance our understanding of whether this approach is a promising therapeutic strategy for the treatment of cancer.

  2. Thiazole-based sigma-1 receptor ligands: Diversity by late-stage C-H arylation of thiazoles, structure affinity and selectivity relationships and molecular interactions

    Bernhard Wünsch, Artur Kokornaczyk, Dirk Schepmann, Junichiro Yamaguchi, Kenichiro Itami, Erik Laurini, Maurizio Fermeglia and Sabrina Pricl

    Accepted manuscript online: 24 MAY 2017 01:20PM EST | DOI: 10.1002/cmdc.201700166

  3. Chemoproteomics-aided medicinal chemistry for the discovery of EPHA2 inhibitors

    Stephanie Heinzlmeir, Jonas Lohse, Tobias Treiber, Denis Kudlinzki, Verena Linhard, Santosh Lakshmi Gande, Sridhar Sreeramulu, Krishna Saxena, Xiaofeng Liu, Mathias Wilhelm, Harald Schwalbe, Bernhard Kuster and Guillaume Médard

    Accepted manuscript online: 24 MAY 2017 07:20AM EST | DOI: 10.1002/cmdc.201700217

  4. Synthesis, ADMET properties, and biological evaluation of benzothiazole compounds targeting CXCR2

    Wesam E. Mehanna, Tiangong Lu, Bikash Debnath, Deena S. Lasheen, Rabah A. T. Serya, Khaled A. Abouzid and Nouri Neamati

    Accepted manuscript online: 23 MAY 2017 09:20PM EST | DOI: 10.1002/cmdc.201700229

  5. Kinome-Wide Profiling Prediction of Small Molecules

    Frieda Anna Sorgenfrei, Simone Fulle and Benjamin Merget

    Accepted manuscript online: 23 MAY 2017 10:20AM EST | DOI: 10.1002/cmdc.201700180

SEARCH

SEARCH BY CITATION